Improvement of salt and pepper skin changes in diffuse scleroderma after treatment with tofacitinib.
作者信息
Nallapati Anshula, Wigley Fredrick M, Paik Julie J
机构信息
Johns Hopkins University, Baltimore, MD, USA.
Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
出版信息
Clin Exp Rheumatol. 2022 Oct;40(10):2008-2009. doi: 10.55563/clinexprheumatol/znqm6v. Epub 2022 Sep 28.
Abstract
摘要
相似文献
1
Improvement of salt and pepper skin changes in diffuse scleroderma after treatment with tofacitinib.托法替布治疗后弥漫性硬皮病中椒盐样皮肤改变的改善
Clin Exp Rheumatol. 2022 Oct;40(10):2008-2009. doi: 10.55563/clinexprheumatol/znqm6v. Epub 2022 Sep 28.
2
Paclitaxel-induced diffuse scleroderma with possible scleroderma-renal crisis: a case report and literature review of taxanes-induced scleroderma.紫杉醇诱导弥漫性硬皮病伴可能的硬皮病-肾危象：1 例病例报告及文献复习。
Clin Rheumatol. 2022 Dec;41(12):3887-3896. doi: 10.1007/s10067-022-06364-z. Epub 2022 Sep 9.
3
Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma.托法替尼对博来霉素诱导的硬皮病小鼠模型的免疫调节作用。
J Dermatol Sci. 2021 Mar;101(3):174-184. doi: 10.1016/j.jdermsci.2020.12.007. Epub 2020 Dec 30.
4
Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis.托法替尼治疗弥漫性皮肤系统性硬皮病皮肤增厚的可能性。
Rheumatology (Oxford). 2021 May 14;60(5):2472-2477. doi: 10.1093/rheumatology/keaa613.
5
Successful use of tofacitinib in the treatment of diffuse systemic sclerosis and axial spondyloarthritis: a case-based review.托法替布治疗弥漫性系统性硬化症和中轴型脊柱关节炎的成功应用：基于病例的综述。
Rheumatol Int. 2021 Mar;41(3):671-675. doi: 10.1007/s00296-020-04767-2. Epub 2021 Jan 12.
6
Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?用于系统性硬化症的酪氨酸激酶抑制剂疗法：何去何从？
Arthritis Rheum. 2011 Nov;63(11):3199-203. doi: 10.1002/art.30545.
7
[How I explore...the revisited toxic path of scleroderma].
Rev Med Liege. 2007 Mar;62(3):170-4.
8
Natural remedies for scleroderma.硬皮病的天然疗法。
Altern Med Rev. 2006 Sep;11(3):188-95.
9
[Scleroderma - prescribing or not hormonal treatment].[硬皮病——是否采用激素治疗]
Rev Assoc Med Bras (1992). 2007 Sep-Oct;53(5):383. doi: 10.1590/s0104-42302007000500007.
10
Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis.托法替布迅速改善了一名系统性硬化症患者的多关节病。
Scand J Rheumatol. 2018 Nov;47(6):505-506. doi: 10.1080/03009742.2017.1387673. Epub 2017 Dec 20.
引用本文的文献
1
Cutaneous dyspigmentation with perifollicular sparing.伴有毛囊周围色素脱失的皮肤色素沉着异常。
JAAD Case Rep. 2024 Aug 13;52:116-119. doi: 10.1016/j.jdcr.2024.07.027. eCollection 2024 Oct.
本文引用的文献
1
Successful treatment with baricitinib of refractory arthritis in a patient with severe diffuse cutaneous systemic sclerosis-rheumatoid arthritis overlap syndrome.巴瑞替尼成功治疗一例患有严重弥漫性皮肤系统性硬化症-类风湿关节炎重叠综合征的难治性关节炎患者。
Clin Exp Rheumatol. 2021 Jul-Aug;39 Suppl 131(4):163-164. doi: 10.55563/clinexprheumatol/gu1ac8. Epub 2021 Jun 15.
2
Vitiligo: an update on systemic treatments.白癜风：系统治疗的最新进展。
Clin Exp Dermatol. 2021 Mar;46(2):248-258. doi: 10.1111/ced.14435. Epub 2020 Dec 22.
3
Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.托法替尼治疗难治性皮肌炎的研究：十例患者开放性先导研究。
Arthritis Rheumatol. 2021 May;73(5):858-865. doi: 10.1002/art.41602. Epub 2021 Mar 24.
4
Salt and Pepper Pigmentation - Skin Manifestation of Systemic Sclerosis.椒盐样色素沉着——系统性硬化症的皮肤表现
J Assoc Physicians India. 2015 Sep;63(9):70.
5
Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo.干扰IFN-γ/CXCL10通路以开发白癜风的新型靶向治疗方法。
Ann Transl Med. 2015 Dec;3(21):343. doi: 10.3978/j.issn.2305-5839.2015.11.36.
Zotero 插件